2-[[4-[(E)-2-phenylethenyl]phenoxy]methyl]oxirane

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 2-[[4-[(E)-2-phenylethenyl]phenoxy]methyl]oxirane
• 化学式: C₁₇H₁₆O₂
• 分子量: 252.31
• InChiKey: PEPWAEBXISDUBD-VOTSOKGWSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  19
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.18
• 拓扑面积：
  21.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] REACTIVE SURFACTANTS<br/>[FR] TENSIOACTIFS RÉACTIFS
  申请人：STEPAN CO

  公开号：WO2020185513A1

  公开（公告）日：2020-09-17

  Processes for making reactive surfactants are disclosed. In one such process, a fatty epoxide, a glycidyl ether, or a combination thereof is reacted with an olefin-functional nucleophile to produce an olefin-functional hydrophobe. The olefin-functional hydrophobe is reacted with ethylene oxide, propylene oxide, butylene oxides, or a combination thereof to produce an alkoxylate. Optionally, the alkoxylate is converted to the corresponding sulfate, phosphate, or maleate. Surfactant compositions comprising the reactive surfactants made by these processes are also described. The invention includes polymerizable mixtures comprising an acrylic monomer and the surfactant compositions as well as aqueous acrylic latex emulsions and coatings produced from the emulsions. The reactive surfactants deliver stable latex emulsions with reduced tendency for surfactant migration or excessive foaming. Coatings from the emulsions have improved wet adhesion, scrub resistance, and water resistance.

  揭示了制备反应性表面活性剂的方法。在其中一种方法中，脂肪环氧化物、环氧乙醚或二者的组合物与烯烃官能核糖核发生反应，从而产生烯烃官能亲水基。将烯烃官能亲水基与环氧乙烷、丙烯酸丙烯酯、丁烯氧化物或二者的组合物发生反应，制备烷氧基化物。可选地，将烷氧基化物转化为相应的硫酸盐、磷酸盐或马来酸盐。还描述了由这些方法制备的含有反应性表面活性剂的表面活性剂组合物。该发明还包括包含丙烯酸单体和表面活性剂组合物的可聚合混合物，以及由这些乳液制备的水性丙烯酸乳胶乳液和涂料。反应性表面活性剂可提供稳定的乳胶乳液，减少表面活性剂迁移或过度起泡的倾向。从这些乳液中制备的涂料具有改善的湿附着力、耐擦洗性和耐水性。
• Foam cell specific Liver X Receptor (LXR) alpha agonist, SIRT1 inhibitors as well as p300 inhibitors as pharmaceutically active agents
  申请人：Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.

  公开号：EP2759295A1

  公开（公告）日：2014-07-30

  The present invention relates to compound (I) and its stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable other LXRα agonist, carrier, excipient and/or diluents. Said compound (I), an LXRα agonist has been identified as useful for the prophylaxis and treatment of atherosclerosis and cardiovascular diseases. Further, the present invention refers to compound (II) and its stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said compound (II), a SIRT1 inhibitor has been identified as useful for the prophylaxis and treatment of neurodegenerative diseases or cancer. Furthermore, the present invention discloses compound (III) and its stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable carrier, excipient and/or diluents. Said compound (III), a p300 inhibitor has been identified as useful for the prophylaxis and treatment of cancer, metabolic, inflammatory, neurodegenerative or cardiovascular diseases.

  本发明涉及化合物（I）及其立体异构体、原药、溶液剂、水合物和/或这些化合物的药学上可接受的盐，以及含有至少一种这些化合物和药学上可接受的其他 LXRα 激动剂、载体、赋形剂和/或稀释剂的药物组合物。所述化合物（I）是一种 LXRα 激动剂，已被确认可用于预防和治疗动脉粥样硬化和心血管疾病。 此外，本发明还涉及化合物（II）及其立体异构体、原药、溶液剂、水合物和/或这些化合物的药学上可接受的盐，以及含有至少一种这些化合物和药学上可接受的载体、赋形剂和/或稀释剂的药物组合物。所述化合物（II）是一种 SIRT1 抑制剂，已被确认可用于预防和治疗神经退行性疾病或癌症。 此外，本发明还公开了化合物（III）及其立体异构体、原药、溶液剂、水合物和/或这些化合物的药学上可接受的盐，以及含有至少一种这些化合物和药学上可接受的载体、赋形剂和/或稀释剂的药物组合物。所述化合物（III）是一种 p300 抑制剂，已被确认可用于预防和治疗癌症、代谢性疾病、炎症、神经退行性疾病或心血管疾病。
• REACTIVE SURFACTANTS
  申请人：Stepan Company

  公开号：EP3935038A1

  公开（公告）日：2022-01-12
• [EN] FOAM CELL SPECIFIC LIVER X RECEPTOR (LXR) ALPHA AGONIST AS PHARMACEUTICALLY ACTIVE AGENT<br/>[FR] AGONISTE ALPHA DU RÉCEPTEUR X DE FOIE (LXR) SPÉCIFIQUE À UNE CELLULE DE MOUSSE EN TANT QU'AGENT PHARMACEUTIQUEMENT ACTIF
  申请人：MAX PLANCK GES ZUR FÖRDERUNG DER WISSENSCHAFTEN E V

  公开号：WO2014118206A1

  公开（公告）日：2014-08-07

  The present invention relates to compound (I) and its stereoisomeric forms, prodrugs, solvates, hydrates and/or pharmaceutically acceptable salts of these compounds as well as pharmaceutical compositions containing at least one of these compounds together with pharmaceutically acceptable other LXRα agonist, carrier, excipient and/or diluents. Said compound (I), an LXRα agonist has been identified as useful for the prophylaxis and treatment of atherosclerosis and cardiovascular diseases.